Inj retacrit non-esrd use
Products billed under this code include Retacrit.
Payment limit per 1000 UNITS, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Retacrit.
Payment limit per 1000 UNITS, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Retacrit | Pfizer Inc | 00069-1305-10 | 20 | $163.42 |
| Retacrit | Pfizer Inc | 00069-1306-10 | 30 | $245.13 |
| Retacrit | Pfizer Inc | 00069-1307-10 | 40 | $326.84 |
| Retacrit | Pfizer Inc | 00069-1308-10 | 100 | $817.10 |
| Retacrit | Pfizer Inc | 00069-1309-04 | 160 | $1,307.36 |
| Retacrit | Pfizer Inc | 00069-1311-10 | 200 | $1,634.20 |
| Retacrit | Pfizer Inc | 00069-1318-10 | 100 | $817.10 |
| Retacrit | Vifor (International) Inc. | 59353-0002-10 | 20 | $163.42 |
| Retacrit | Vifor (International) Inc. | 59353-0003-10 | 30 | $245.13 |
| Retacrit | Vifor (International) Inc. | 59353-0004-10 | 40 | $326.84 |
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Retacrit | Vifor (International) Inc. | 59353-0120-10 | 200 | $1,634.20 |
| Retacrit | Vifor (International) Inc. | 59353-0220-10 | 100 | $817.10 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $8.171 | +$0.203 | 1000 UNITS | Inj retacrit non-esrd use | v1, posted September 17, 2026 |
| 3Q26 | $7.968 | +$0.085 | 1000 UNITS | Inj retacrit non-esrd use | v1, posted September 15, 2026 |
| 2Q26 | $7.883 | +$0.316 | 1000 UNITS | Inj retacrit non-esrd use | v1, posted September 15, 2026 |
| 1Q26 | $7.567 | −$0.284 | 1000 UNITS | Inj retacrit non-esrd use | v1, posted September 15, 2026 |
| 4Q25 | $7.851 | +$0.285 | 1000 UNITS | Inj retacrit non-esrd use | v1, posted September 8, 2026 |
| 3Q25 | $7.566 | +$0.496 | 1000 UNITS | Inj retacrit non-esrd use | v1, posted March 10, 2026 |
| 2Q25 | $7.07 | −$0.399 | 1000 UNITS | Inj retacrit non-esrd use | v1, posted March 10, 2026 |
| 1Q25 | $7.469 | −$0.149 | 1000 UNITS | Inj retacrit non-esrd use | v1, posted December 19, 2025 |
| 4Q24 | $7.618 | +$0.798 | 1000 UNITS | Inj retacrit non-esrd use | v1, posted June 11, 2025 |
| 3Q24 | $6.82 | −$0.691 | 1000 UNITS | Inj retacrit non-esrd use | v1, posted June 11, 2025 |
| 2Q24 | $7.511 | −$0.313 | 1000 UNITS | Inj retacrit non-esrd use | v1, posted March 11, 2025 |
| 1Q24 | $7.824 | +$0.572 | 1000 UNITS | Inj retacrit non-esrd use | v1, posted December 19, 2024 |
| 4Q23 | $7.252 | +$0.029 | 1000 UNITS | Inj retacrit non-esrd use | v1, posted October 10, 2024 |
| 3Q23 | $7.223 | −$1.157 | 1000 UNITS | Inj retacrit non-esrd use | v1, posted June 5, 2024 |
| 2Q23 | $8.38 | +$0.473 | 1000 UNITS | Inj retacrit non-esrd use | v1, posted February 23, 2024 |
| 1Q23 | $7.907 | −$0.227 | 1000 UNITS | Inj retacrit non-esrd use | v1, posted December 6, 2023 |
| 4Q22 | $8.134 | −$0.261 | 1000 UNITS | Inj retacrit non-esrd use | v1, posted June 22, 2023 |
| 3Q22 | $8.395 | +$0.139 | 1000 UNITS | Inj retacrit non-esrd use | v1, posted June 9, 2023 |
| 2Q22 | $8.256 | +$0.13 | 1000 UNITS | Inj retacrit non-esrd use | v1, posted December 14, 2022 |
| 1Q22 | $8.126 | −$0.529 | 1000 UNITS | Inj retacrit non-esrd use | v1, posted June 8, 2022 |
| 4Q21 | $8.655 | +$0.03 | 1000 UNITS | Inj retacrit non-esrd use | v1, posted June 2, 2022 |
| 3Q21 | $8.625 | −$0.565 | 1000 UNITS | Inj retacrit non-esrd use | v1, posted June 2, 2022 |
| 2Q21 | $9.19 | +$0.643 | 1000 UNITS | Inj retacrit non-esrd use | v1, posted March 1, 2022 |
| 1Q21 | $8.547 | – | 1000 UNITS | Inj retacrit non-esrd use | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.